Litcius/Paper detail

Repurposing the Ebola and Marburg Virus Inhibitors Tilorone, Quinacrine, and Pyronaridine: <i>In Vitro</i> Activity against SARS-CoV-2 and Potential Mechanisms

Ana C. Puhl, Ethan J. Fritch, Thomas R. Lane, Longping V. Tse, Boyd L. Yount, Carolina Q. Sacramento, Natalia Fintelman‐Rodrigues, Tatyana Almeida Tavella, Fábio Trindade Maranhão Costa, Stuart Weston, James Logue, Matthew B. Frieman, Lakshmanane Premkumar, Kenneth H. Pearce, Brett L. Hurst, Carolina Horta Andrade, James A. Levi, Nicole J. Johnson, Samantha C. Kisthardt, Frank Scholle, Thiago Moreno L. Souza, Nathaniel J. Moorman, Ralph S. Baric, Peter B. Madrid, Sean Ekins

2021ACS Omega76 citationsDOIOpen Access PDF

Abstract

observed in A549-ACE2 cells. We also provide novel insights into the mechanism of these compounds which is likely lysosomotropic.

Topics & Concepts

Ebola virusMarburg virusIn vivoVirologyDrug repositioningIn vitroIC50Viral replicationCoronavirusEbolavirusVirusPharmacologyBiologyChemistryDrugMedicineCoronavirus disease 2019 (COVID-19)DiseaseInfectious disease (medical specialty)BiochemistryBiotechnologyPathologyViral Infections and Outbreaks ResearchSARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research Studies
Repurposing the Ebola and Marburg Virus Inhibitors Tilorone, Quinacrine, and Pyronaridine: <i>In Vitro</i> Activity against SARS-CoV-2 and Potential Mechanisms | Litcius